Previous Close | 21.05 |
Open | 20.64 |
Bid | 20.75 x 0 |
Ask | 20.78 x 0 |
Day's Range | 20.51 - 20.86 |
52 Week Range | 6.73 - 21.30 |
Volume | 576,910 |
Avg. Volume | 1,675,232 |
Market Cap | 5.653B |
Beta (5Y Monthly) | 1.74 |
PE Ratio (TTM) | 111.61 |
EPS (TTM) | 0.19 |
Earnings Date | Mar. 01, 2021 - Mar. 05, 2021 |
Forward Dividend & Yield | 0.56 (2.67%) |
Ex-Dividend Date | Sep. 14, 2020 |
1y Target Est | 27.60 |
Patients aged 70 or younger with previously untreated CLL lived longer without disease progression compared to patients treated with FCR, a chemoimmunotherapy regimenTORONTO, Jan. 13, 2021 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).
Here’s why value investors bullish on a recovery in the latter half of 2021 have a quality pick in Tourmaline Oil (TSX:TOU).The post Buy This 1 High-Quality Value Stock for a 2021 Recovery appeared first on The Motley Fool Canada.
This article will reflect on the compensation paid to Mike Rose who has served as CEO of Tourmaline Oil Corp. ( TSE:TOU...